A PHP Error was encountered

Severity: Warning

Message: fopen(/var/cpanel/php/sessions/ea-php72/ci_session5789e3fd257e4e2b7e13a5a08a11654924cda29c): failed to open stream: No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 176

Backtrace:

File: /home/rejovjcx/mraccuracyreports.com/application/controllers/Reportdetails.php
Line: 10
Function: library

File: /home/rejovjcx/mraccuracyreports.com/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: session_start(): Failed to read session data: user (path: /var/cpanel/php/sessions/ea-php72)

Filename: Session/Session.php

Line Number: 143

Backtrace:

File: /home/rejovjcx/mraccuracyreports.com/application/controllers/Reportdetails.php
Line: 10
Function: library

File: /home/rejovjcx/mraccuracyreports.com/index.php
Line: 315
Function: require_once

Global Peptide and Oligonucleotide CDMO Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application

img

Global Peptide and Oligonucleotide CDMO Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical

Publisher : MRA | Format : PDF

Global Peptide and Oligonucleotide CDMO Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application

Peptide and Oligonucleotide CDMO report published by MRAResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Peptide and Oligonucleotide CDMO market is projected to reach US$ 3117.9 million in 2033, increasing from US$ 1600 million in 2022, with the CAGR of 10.0% during the period of 2023 to 2033. Demand from Pharmaceutical and Biotechnology Companies and Research Institutes are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Peptide and Oligonucleotide CDMO industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2033.
Globally, Peptide and Oligonucleotide CDMO key companies include Lonza Group Ltd., Thermo Fisher Scientific Inc., Merck KGaA, Catalent, Inc., Genscript Biotech Corporation, Polypeptide Group, Bachem Holding AG, Wuxi Apptec Co., Ltd. and Ajinomoto Co., Inc., etc. Lonza Group Ltd., Thermo Fisher Scientific Inc., Merck KGaA are top 3 players and held % share in total in 2022.
Peptide and Oligonucleotide CDMO can be divided into Peptide CDMO and Oligonucleotide CDMO, etc. Peptide CDMO is the mainstream product in the market, accounting for % share globally in 2022.
Peptide and Oligonucleotide CDMO is widely used in various fields, such as Pharmaceutical and Biotechnology Companies, Research Institutes and Others,, etc. Pharmaceutical and Biotechnology Companies provides greatest supports to the Peptide and Oligonucleotide CDMO industry development. In 2022, global % share of Peptide and Oligonucleotide CDMO went into Pharmaceutical and Biotechnology Companies filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Peptide and Oligonucleotide CDMO market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report



By Company


Lonza Group Ltd.
Thermo Fisher Scientific Inc.
Merck KGaA
Catalent, Inc.
Genscript Biotech Corporation
Polypeptide Group
Bachem Holding AG
Wuxi Apptec Co., Ltd.
Ajinomoto Co., Inc.
Rentschler Biopharma SE
Corden Pharma GmbH
Senn Chemicals AG
Almac Group
Lonza Custom Manufacturing
Creative Peptides
Swiss Customized Synthesis
Syngene
Eurogentec
Segment by Type
Peptide CDMO
Oligonucleotide CDMO

Segment by Application


Pharmaceutical and Biotechnology Companies
Research Institutes
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries

Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia

Latin America
Mexico
Brazil

Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Peptide and Oligonucleotide CDMO market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2033).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Peptide and Oligonucleotide CDMO introduction, etc. Peptide and Oligonucleotide CDMO Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12MRAResearch’s Conclusions of Peptide and Oligonucleotide CDMO market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by MRAResearch.

Table of Content

1 Market Overview of Peptide and Oligonucleotide CDMO
1.1 Peptide and Oligonucleotide CDMO Market Overview
1.1.1 Peptide and Oligonucleotide CDMO Product Scope
1.1.2 Peptide and Oligonucleotide CDMO Market Status and Outlook
1.2 Global Peptide and Oligonucleotide CDMO Market Size Overview by Region 2018 VS 2022 VS 2033
1.3 Global Peptide and Oligonucleotide CDMO Market Size by Region (2018-2033)
1.4 Global Peptide and Oligonucleotide CDMO Historic Market Size by Region (2018-2023)
1.5 Global Peptide and Oligonucleotide CDMO Market Size Forecast by Region (2024-2033)
1.6 Key Regions, Peptide and Oligonucleotide CDMO Market Size (2018-2033)
1.6.1 North America Peptide and Oligonucleotide CDMO Market Size (2018-2033)
1.6.2 Europe Peptide and Oligonucleotide CDMO Market Size (2018-2033)
1.6.3 Asia-Pacific Peptide and Oligonucleotide CDMO Market Size (2018-2033)
1.6.4 Latin America Peptide and Oligonucleotide CDMO Market Size (2018-2033)
1.6.5 Middle East & Africa Peptide and Oligonucleotide CDMO Market Size (2018-2033)
2 Peptide and Oligonucleotide CDMO Market by Type
2.1 Introduction
2.1.1 Peptide CDMO
2.1.2 Oligonucleotide CDMO
2.2 Global Peptide and Oligonucleotide CDMO Market Size by Type: 2018 VS 2022 VS 2033
2.2.1 Global Peptide and Oligonucleotide CDMO Historic Market Size by Type (2018-2023)
2.2.2 Global Peptide and Oligonucleotide CDMO Forecasted Market Size by Type (2024-2033)
2.3 Key Regions Market Size by Type
2.3.1 North America Peptide and Oligonucleotide CDMO Revenue Breakdown by Type (2018-2033)
2.3.2 Europe Peptide and Oligonucleotide CDMO Revenue Breakdown by Type (2018-2033)
2.3.3 Asia-Pacific Peptide and Oligonucleotide CDMO Revenue Breakdown by Type (2018-2033)
2.3.4 Latin America Peptide and Oligonucleotide CDMO Revenue Breakdown by Type (2018-2033)
2.3.5 Middle East and Africa Peptide and Oligonucleotide CDMO Revenue Breakdown by Type (2018-2033)
3 Peptide and Oligonucleotide CDMO Market Overview by Application
3.1 Introduction
3.1.1 Pharmaceutical and Biotechnology Companies
3.1.2 Research Institutes
3.1.3 Others
3.2 Global Peptide and Oligonucleotide CDMO Market Size by Application: 2018 VS 2022 VS 2033
3.2.1 Global Peptide and Oligonucleotide CDMO Historic Market Size by Application (2018-2023)
3.2.2 Global Peptide and Oligonucleotide CDMO Forecasted Market Size by Application (2024-2033)
3.3 Key Regions Market Size by Application
3.3.1 North America Peptide and Oligonucleotide CDMO Revenue Breakdown by Application (2018-2033)
3.3.2 Europe Peptide and Oligonucleotide CDMO Revenue Breakdown by Application (2018-2033)
3.3.3 Asia-Pacific Peptide and Oligonucleotide CDMO Revenue Breakdown by Application (2018-2033)
3.3.4 Latin America Peptide and Oligonucleotide CDMO Revenue Breakdown by Application (2018-2033)
3.3.5 Middle East and Africa Peptide and Oligonucleotide CDMO Revenue Breakdown by Application (2018-2033)
4 Peptide and Oligonucleotide CDMO Competition Analysis by Players
4.1 Global Peptide and Oligonucleotide CDMO Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Peptide and Oligonucleotide CDMO as of 2022)
4.3 Date of Key Players Enter into Peptide and Oligonucleotide CDMO Market
4.4 Global Top Players Peptide and Oligonucleotide CDMO Headquarters and Area Served
4.5 Key Players Peptide and Oligonucleotide CDMO Product Solution and Service
4.6 Competitive Status
4.6.1 Peptide and Oligonucleotide CDMO Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Lonza Group Ltd.
5.1.1 Lonza Group Ltd. Profile
5.1.2 Lonza Group Ltd. Main Business
5.1.3 Lonza Group Ltd. Peptide and Oligonucleotide CDMO Products, Services and Solutions
5.1.4 Lonza Group Ltd. Peptide and Oligonucleotide CDMO Revenue (US$ Million) & (2018-2023)
5.1.5 Lonza Group Ltd. Recent Developments
5.2 Thermo Fisher Scientific Inc.
5.2.1 Thermo Fisher Scientific Inc. Profile
5.2.2 Thermo Fisher Scientific Inc. Main Business
5.2.3 Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Products, Services and Solutions
5.2.4 Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Revenue (US$ Million) & (2018-2023)
5.2.5 Thermo Fisher Scientific Inc. Recent Developments
5.3 Merck KGaA
5.3.1 Merck KGaA Profile
5.3.2 Merck KGaA Main Business
5.3.3 Merck KGaA Peptide and Oligonucleotide CDMO Products, Services and Solutions
5.3.4 Merck KGaA Peptide and Oligonucleotide CDMO Revenue (US$ Million) & (2018-2023)
5.3.5 Catalent, Inc. Recent Developments
5.4 Catalent, Inc.
5.4.1 Catalent, Inc. Profile
5.4.2 Catalent, Inc. Main Business
5.4.3 Catalent, Inc. Peptide and Oligonucleotide CDMO Products, Services and Solutions
5.4.4 Catalent, Inc. Peptide and Oligonucleotide CDMO Revenue (US$ Million) & (2018-2023)
5.4.5 Catalent, Inc. Recent Developments
5.5 Genscript Biotech Corporation
5.5.1 Genscript Biotech Corporation Profile
5.5.2 Genscript Biotech Corporation Main Business
5.5.3 Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Products, Services and Solutions
5.5.4 Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Revenue (US$ Million) & (2018-2023)
5.5.5 Genscript Biotech Corporation Recent Developments
5.6 Polypeptide Group
5.6.1 Polypeptide Group Profile
5.6.2 Polypeptide Group Main Business
5.6.3 Polypeptide Group Peptide and Oligonucleotide CDMO Products, Services and Solutions
5.6.4 Polypeptide Group Peptide and Oligonucleotide CDMO Revenue (US$ Million) & (2018-2023)
5.6.5 Polypeptide Group Recent Developments
5.7 Bachem Holding AG
5.7.1 Bachem Holding AG Profile
5.7.2 Bachem Holding AG Main Business
5.7.3 Bachem Holding AG Peptide and Oligonucleotide CDMO Products, Services and Solutions
5.7.4 Bachem Holding AG Peptide and Oligonucleotide CDMO Revenue (US$ Million) & (2018-2023)
5.7.5 Bachem Holding AG Recent Developments
5.8 Wuxi Apptec Co., Ltd.
5.8.1 Wuxi Apptec Co., Ltd. Profile
5.8.2 Wuxi Apptec Co., Ltd. Main Business
5.8.3 Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Products, Services and Solutions
5.8.4 Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Revenue (US$ Million) & (2018-2023)
5.8.5 Wuxi Apptec Co., Ltd. Recent Developments
5.9 Ajinomoto Co., Inc.
5.9.1 Ajinomoto Co., Inc. Profile
5.9.2 Ajinomoto Co., Inc. Main Business
5.9.3 Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Products, Services and Solutions
5.9.4 Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Revenue (US$ Million) & (2018-2023)
5.9.5 Ajinomoto Co., Inc. Recent Developments
5.10 Rentschler Biopharma SE
5.10.1 Rentschler Biopharma SE Profile
5.10.2 Rentschler Biopharma SE Main Business
5.10.3 Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Products, Services and Solutions
5.10.4 Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Revenue (US$ Million) & (2018-2023)
5.10.5 Rentschler Biopharma SE Recent Developments
5.11 Corden Pharma GmbH
5.11.1 Corden Pharma GmbH Profile
5.11.2 Corden Pharma GmbH Main Business
5.11.3 Corden Pharma GmbH Peptide and Oligonucleotide CDMO Products, Services and Solutions
5.11.4 Corden Pharma GmbH Peptide and Oligonucleotide CDMO Revenue (US$ Million) & (2018-2023)
5.11.5 Corden Pharma GmbH Recent Developments
5.12 Senn Chemicals AG
5.12.1 Senn Chemicals AG Profile
5.12.2 Senn Chemicals AG Main Business
5.12.3 Senn Chemicals AG Peptide and Oligonucleotide CDMO Products, Services and Solutions
5.12.4 Senn Chemicals AG Peptide and Oligonucleotide CDMO Revenue (US$ Million) & (2018-2023)
5.12.5 Senn Chemicals AG Recent Developments
5.13 Almac Group
5.13.1 Almac Group Profile
5.13.2 Almac Group Main Business
5.13.3 Almac Group Peptide and Oligonucleotide CDMO Products, Services and Solutions
5.13.4 Almac Group Peptide and Oligonucleotide CDMO Revenue (US$ Million) & (2018-2023)
5.13.5 Almac Group Recent Developments
5.14 Lonza Custom Manufacturing
5.14.1 Lonza Custom Manufacturing Profile
5.14.2 Lonza Custom Manufacturing Main Business
5.14.3 Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Products, Services and Solutions
5.14.4 Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Revenue (US$ Million) & (2018-2023)
5.14.5 Lonza Custom Manufacturing Recent Developments
5.15 Creative Peptides
5.15.1 Creative Peptides Profile
5.15.2 Creative Peptides Main Business
5.15.3 Creative Peptides Peptide and Oligonucleotide CDMO Products, Services and Solutions
5.15.4 Creative Peptides Peptide and Oligonucleotide CDMO Revenue (US$ Million) & (2018-2023)
5.15.5 Creative Peptides Recent Developments
5.16 Swiss Customized Synthesis
5.16.1 Swiss Customized Synthesis Profile
5.16.2 Swiss Customized Synthesis Main Business
5.16.3 Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Products, Services and Solutions
5.16.4 Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Revenue (US$ Million) & (2018-2023)
5.16.5 Swiss Customized Synthesis Recent Developments
5.17 Syngene
5.17.1 Syngene Profile
5.17.2 Syngene Main Business
5.17.3 Syngene Peptide and Oligonucleotide CDMO Products, Services and Solutions
5.17.4 Syngene Peptide and Oligonucleotide CDMO Revenue (US$ Million) & (2018-2023)
5.17.5 Syngene Recent Developments
5.18 Eurogentec
5.18.1 Eurogentec Profile
5.18.2 Eurogentec Main Business
5.18.3 Eurogentec Peptide and Oligonucleotide CDMO Products, Services and Solutions
5.18.4 Eurogentec Peptide and Oligonucleotide CDMO Revenue (US$ Million) & (2018-2023)
5.18.5 Eurogentec Recent Developments
6 North America
6.1 North America Peptide and Oligonucleotide CDMO Market Size by Country (2018-2033)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Peptide and Oligonucleotide CDMO Market Size by Country (2018-2033)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Peptide and Oligonucleotide CDMO Market Size by Region (2018-2033)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Peptide and Oligonucleotide CDMO Market Size by Country (2018-2033)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Country (2018-2033)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Peptide and Oligonucleotide CDMO Market Dynamics
11.1 Peptide and Oligonucleotide CDMO Industry Trends
11.2 Peptide and Oligonucleotide CDMO Market Drivers
11.3 Peptide and Oligonucleotide CDMO Market Challenges
11.4 Peptide and Oligonucleotide CDMO Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List

List of Figure

List of Tables
Table 1. Global Market Peptide and Oligonucleotide CDMO Market Size (US$ Million) Comparison by Region 2018 VS 2022 VS 2033
Table 2. Global Peptide and Oligonucleotide CDMO Market Size by Region (2018-2023) & (US$ Million)
Table 3. Global Peptide and Oligonucleotide CDMO Market Size Share by Region (2018-2023)
Table 4. Global Peptide and Oligonucleotide CDMO Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 5. Global Peptide and Oligonucleotide CDMO Forecasted Market Size Share by Region (2024-2033)
Table 6. Global Peptide and Oligonucleotide CDMO Market Size (US$ Million) by Type: 2018 VS 2022 VS 2033
Table 7. Global Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023) & (US$ Million)
Table 8. Global Peptide and Oligonucleotide CDMO Revenue Market Share by Type (2018-2023)
Table 9. Global Peptide and Oligonucleotide CDMO Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 10. Global Peptide and Oligonucleotide CDMO Revenue Market Share by Type (2024-2033)
Table 11. North America Peptide and Oligonucleotide CDMO Revenue by Type (2018-2023) & (US$ Million)
Table 12. North America Peptide and Oligonucleotide CDMO Revenue by Type (2024-2033) & (US$ Million)
Table 13. Europe Peptide and Oligonucleotide CDMO Revenue by Type (2018-2023) & (US$ Million)
Table 14. Europe Peptide and Oligonucleotide CDMO Revenue by Type (2024-2033) & (US$ Million)
Table 15. Asia-Pacific Peptide and Oligonucleotide CDMO Revenue by Type (2018-2023) & (US$ Million)
Table 16. Asia-Pacific Peptide and Oligonucleotide CDMO Revenue by Type (2024-2033) & (US$ Million)
Table 17. Latin America Peptide and Oligonucleotide CDMO Revenue by Type (2018-2023) & (US$ Million)
Table 18. Latin America Peptide and Oligonucleotide CDMO Revenue by Type (2024-2033) & (US$ Million)
Table 19. Middle East and Africa Peptide and Oligonucleotide CDMO Revenue by Type (2018-2023) & (US$ Million)
Table 20. Middle East and Africa Peptide and Oligonucleotide CDMO Revenue by Type (2024-2033) & (US$ Million)
Table 21. Global Peptide and Oligonucleotide CDMO Market Size (US$ Million) by Application: 2018 VS 2022 VS 2033
Table 22. Global Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023) & (US$ Million)
Table 23. Global Peptide and Oligonucleotide CDMO Revenue Market Share by Application (2018-2023)
Table 24. Global Peptide and Oligonucleotide CDMO Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 25. Global Peptide and Oligonucleotide CDMO Revenue Market Share by Application (2024-2033)
Table 26. North America Peptide and Oligonucleotide CDMO Revenue by Application (2018-2023) & (US$ Million)
Table 27. North America Peptide and Oligonucleotide CDMO Revenue by Application (2024-2033) & (US$ Million)
Table 28. Europe Peptide and Oligonucleotide CDMO Revenue by Application (2018-2023) & (US$ Million)
Table 29. Europe Peptide and Oligonucleotide CDMO Revenue by Application (2024-2033) & (US$ Million)
Table 30. Asia-Pacific Peptide and Oligonucleotide CDMO Revenue by Application (2018-2023) & (US$ Million)
Table 31. Asia-Pacific Peptide and Oligonucleotide CDMO Revenue by Application (2024-2033) & (US$ Million)
Table 32. Latin America Peptide and Oligonucleotide CDMO Revenue by Application (2018-2023) & (US$ Million)
Table 33. Latin America Peptide and Oligonucleotide CDMO Revenue by Application (2024-2033) & (US$ Million)
Table 34. Middle East and Africa Peptide and Oligonucleotide CDMO Revenue by Application (2018-2023) & (US$ Million)
Table 35. Middle East and Africa Peptide and Oligonucleotide CDMO Revenue by Application (2024-2033) & (US$ Million)
Table 36. Global Peptide and Oligonucleotide CDMO Revenue (US$ Million) by Players (2018-2023)
Table 37. Global Peptide and Oligonucleotide CDMO Revenue Market Share by Players (2018-2023)
Table 38. Global Top Players Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Peptide and Oligonucleotide CDMO as of 2022)
Table 39. Date of Key Players Enter into Peptide and Oligonucleotide CDMO Market
Table 40. Global Peptide and Oligonucleotide CDMO Key Players Headquarters and Area Served
Table 41. Peptide and Oligonucleotide CDMO Product Solution and Service
Table 42. Global Peptide and Oligonucleotide CDMO Players Market Concentration Ratio (CR5 and HHI)
Table 43. Mergers & Acquisitions, Expansion Plans
Table 44. Lonza Group Ltd. Basic Information List
Table 45. Lonza Group Ltd. Description and Business Overview
Table 46. Lonza Group Ltd. Peptide and Oligonucleotide CDMO Products, Services and Solutions
Table 47. Revenue (US$ Million) in Peptide and Oligonucleotide CDMO Business of Lonza Group Ltd. (2018-2023)
Table 48. Lonza Group Ltd. Recent Developments
Table 49. Thermo Fisher Scientific Inc. Basic Information List
Table 50. Thermo Fisher Scientific Inc. Description and Business Overview
Table 51. Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Products, Services and Solutions
Table 52. Revenue (US$ Million) in Peptide and Oligonucleotide CDMO Business of Thermo Fisher Scientific Inc. (2018-2023)
Table 53. Thermo Fisher Scientific Inc. Recent Developments
Table 54. Merck KGaA Basic Information List
Table 55. Merck KGaA Description and Business Overview
Table 56. Merck KGaA Peptide and Oligonucleotide CDMO Products, Services and Solutions
Table 57. Revenue (US$ Million) in Peptide and Oligonucleotide CDMO Business of Merck KGaA (2018-2023)
Table 58. Merck KGaA Recent Developments
Table 59. Catalent, Inc. Basic Information List
Table 60. Catalent, Inc. Description and Business Overview
Table 61. Catalent, Inc. Peptide and Oligonucleotide CDMO Products, Services and Solutions
Table 62. Revenue (US$ Million) in Peptide and Oligonucleotide CDMO Business of Catalent, Inc. (2018-2023)
Table 63. Catalent, Inc. Recent Developments
Table 64. Genscript Biotech Corporation Basic Information List
Table 65. Genscript Biotech Corporation Description and Business Overview
Table 66. Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Products, Services and Solutions
Table 67. Revenue (US$ Million) in Peptide and Oligonucleotide CDMO Business of Genscript Biotech Corporation (2018-2023)
Table 68. Genscript Biotech Corporation Recent Developments
Table 69. Polypeptide Group Basic Information List
Table 70. Polypeptide Group Description and Business Overview
Table 71. Polypeptide Group Peptide and Oligonucleotide CDMO Products, Services and Solutions
Table 72. Revenue (US$ Million) in Peptide and Oligonucleotide CDMO Business of Polypeptide Group (2018-2023)
Table 73. Polypeptide Group Recent Developments
Table 74. Bachem Holding AG Basic Information List
Table 75. Bachem Holding AG Description and Business Overview
Table 76. Bachem Holding AG Peptide and Oligonucleotide CDMO Products, Services and Solutions
Table 77. Revenue (US$ Million) in Peptide and Oligonucleotide CDMO Business of Bachem Holding AG (2018-2023)
Table 78. Bachem Holding AG Recent Developments
Table 79. Wuxi Apptec Co., Ltd. Basic Information List
Table 80. Wuxi Apptec Co., Ltd. Description and Business Overview
Table 81. Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Products, Services and Solutions
Table 82. Revenue (US$ Million) in Peptide and Oligonucleotide CDMO Business of Wuxi Apptec Co., Ltd. (2018-2023)
Table 83. Wuxi Apptec Co., Ltd. Recent Developments
Table 84. Ajinomoto Co., Inc. Basic Information List
Table 85. Ajinomoto Co., Inc. Description and Business Overview
Table 86. Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Products, Services and Solutions
Table 87. Revenue (US$ Million) in Peptide and Oligonucleotide CDMO Business of Ajinomoto Co., Inc. (2018-2023)
Table 88. Ajinomoto Co., Inc. Recent Developments
Table 89. Rentschler Biopharma SE Basic Information List
Table 90. Rentschler Biopharma SE Description and Business Overview
Table 91. Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Products, Services and Solutions
Table 92. Revenue (US$ Million) in Peptide and Oligonucleotide CDMO Business of Rentschler Biopharma SE (2018-2023)
Table 93. Rentschler Biopharma SE Recent Developments
Table 94. Corden Pharma GmbH Basic Information List
Table 95. Corden Pharma GmbH Description and Business Overview
Table 96. Corden Pharma GmbH Peptide and Oligonucleotide CDMO Products, Services and Solutions
Table 97. Revenue (US$ Million) in Peptide and Oligonucleotide CDMO Business of Corden Pharma GmbH (2018-2023)
Table 98. Corden Pharma GmbH Recent Developments
Table 99. Senn Chemicals AG Basic Information List
Table 100. Senn Chemicals AG Description and Business Overview
Table 101. Senn Chemicals AG Peptide and Oligonucleotide CDMO Products, Services and Solutions
Table 102. Revenue (US$ Million) in Peptide and Oligonucleotide CDMO Business of Senn Chemicals AG (2018-2023)
Table 103. Senn Chemicals AG Recent Developments
Table 104. Almac Group Basic Information List
Table 105. Almac Group Description and Business Overview
Table 106. Almac Group Peptide and Oligonucleotide CDMO Products, Services and Solutions
Table 107. Revenue (US$ Million) in Peptide and Oligonucleotide CDMO Business of Almac Group (2018-2023)
Table 108. Almac Group Recent Developments
Table 109. Lonza Custom Manufacturing Basic Information List
Table 110. Lonza Custom Manufacturing Description and Business Overview
Table 111. Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Products, Services and Solutions
Table 112. Revenue (US$ Million) in Peptide and Oligonucleotide CDMO Business of Lonza Custom Manufacturing (2018-2023)
Table 113. Lonza Custom Manufacturing Recent Developments
Table 114. Creative Peptides Basic Information List
Table 115. Creative Peptides Description and Business Overview
Table 116. Creative Peptides Peptide and Oligonucleotide CDMO Products, Services and Solutions
Table 117. Revenue (US$ Million) in Peptide and Oligonucleotide CDMO Business of Creative Peptides (2018-2023)
Table 118. Creative Peptides Recent Developments
Table 119. Swiss Customized Synthesis Basic Information List
Table 120. Swiss Customized Synthesis Description and Business Overview
Table 121. Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Products, Services and Solutions
Table 122. Revenue (US$ Million) in Peptide and Oligonucleotide CDMO Business of Swiss Customized Synthesis (2018-2023)
Table 123. Swiss Customized Synthesis Recent Developments
Table 124. Syngene Basic Information List
Table 125. Syngene Description and Business Overview
Table 126. Syngene Peptide and Oligonucleotide CDMO Products, Services and Solutions
Table 127. Revenue (US$ Million) in Peptide and Oligonucleotide CDMO Business of Syngene (2018-2023)
Table 128. Syngene Recent Developments
Table 129. Eurogentec Basic Information List
Table 130. Eurogentec Description and Business Overview
Table 131. Eurogentec Peptide and Oligonucleotide CDMO Products, Services and Solutions
Table 132. Revenue (US$ Million) in Peptide and Oligonucleotide CDMO Business of Eurogentec (2018-2023)
Table 133. Eurogentec Recent Developments
Table 134. North America Peptide and Oligonucleotide CDMO Market Size by Country (2018-2023) & (US$ Million)
Table 135. North America Peptide and Oligonucleotide CDMO Market Size by Country (2024-2033) & (US$ Million)
Table 136. Europe Peptide and Oligonucleotide CDMO Market Size by Country (2018-2023) & (US$ Million)
Table 137. Europe Peptide and Oligonucleotide CDMO Market Size by Country (2024-2033) & (US$ Million)
Table 138. Asia-Pacific Peptide and Oligonucleotide CDMO Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 139. Asia-Pacific Peptide and Oligonucleotide CDMO Market Size by Region (2018-2023) & (US$ Million)
Table 140. Asia-Pacific Peptide and Oligonucleotide CDMO Market Size by Region (2024-2033) & (US$ Million)
Table 141. Asia-Pacific Peptide and Oligonucleotide CDMO Market Share by Region (2018-2023)
Table 142. Asia-Pacific Peptide and Oligonucleotide CDMO Market Share by Region (2024-2033)
Table 143. Latin America Peptide and Oligonucleotide CDMO Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 144. Latin America Peptide and Oligonucleotide CDMO Market Size by Country (2018-2023) & (US$ Million)
Table 145. Latin America Peptide and Oligonucleotide CDMO Market Size by Country (2024-2033) & (US$ Million)
Table 146. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 147. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Country (2018-2023) & (US$ Million)
Table 148. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Country (2024-2033) & (US$ Million)
Table 149. Peptide and Oligonucleotide CDMO Market Trends
Table 150. Peptide and Oligonucleotide CDMO Market Drivers
Table 151. Peptide and Oligonucleotide CDMO Market Challenges
Table 152. Peptide and Oligonucleotide CDMO Market Restraints
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Peptide and Oligonucleotide CDMO Market Size Year-over-Year 2018-2033 & (US$ Million)
Figure 2. Global Peptide and Oligonucleotide CDMO Market Size (US$ Million), 2018 VS 2022 VS 2033
Figure 3. Global Peptide and Oligonucleotide CDMO Market Share by Regions: 2022 VS 2033
Figure 4. Global Peptide and Oligonucleotide CDMO Forecasted Market Size Share by Region (2024-2033)
Figure 5. North America Peptide and Oligonucleotide CDMO Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 6. Europe Peptide and Oligonucleotide CDMO Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 7. Asia-Pacific Peptide and Oligonucleotide CDMO Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 8. Latin America Peptide and Oligonucleotide CDMO Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 9. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 10. Product Picture of Peptide CDMO
Figure 11. Global Peptide CDMO Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 12. Product Picture of Oligonucleotide CDMO
Figure 13. Global Oligonucleotide CDMO Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 14. Global Peptide and Oligonucleotide CDMO Market Size Share by Type: 2022 & 2033
Figure 15. North America Peptide and Oligonucleotide CDMO Revenue Market Share by Type (2018-2033)
Figure 16. Europe Peptide and Oligonucleotide CDMO Revenue Market Share by Type (2018-2033)
Figure 17. Asia-Pacific Peptide and Oligonucleotide CDMO Revenue Market Share by Type (2018-2033)
Figure 18. Latin America Peptide and Oligonucleotide CDMO Revenue Market Share by Type (2018-2033)
Figure 19. Middle East and Africa Peptide and Oligonucleotide CDMO Revenue Market Share by Type (2018-2033)
Figure 20. Pharmaceutical and Biotechnology Companies Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 21. Research Institutes Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 22. Others Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 23. Global Peptide and Oligonucleotide CDMO Market Size Share by Application: 2022 & 2033
Figure 24. North America Peptide and Oligonucleotide CDMO Revenue Market Share by Application (2018-2033)
Figure 25. Europe Peptide and Oligonucleotide CDMO Revenue Market Share by Application (2018-2033)
Figure 26. Asia-Pacific Peptide and Oligonucleotide CDMO Revenue Market Share by Application (2018-2033)
Figure 27. Latin America Peptide and Oligonucleotide CDMO Revenue Market Share by Application (2018-2033)
Figure 28. Middle East and Africa Peptide and Oligonucleotide CDMO Revenue Market Share by Application (2018-2033)
Figure 29. Peptide and Oligonucleotide CDMO Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 30. Global Top 5 and Top 10 Players Peptide and Oligonucleotide CDMO Market Share in 2022
Figure 31. North America Peptide and Oligonucleotide CDMO Market Share by Country (2018-2033)
Figure 32. United States Peptide and Oligonucleotide CDMO Market Size (2018-2033) & (US$ Million)
Figure 33. Canada Peptide and Oligonucleotide CDMO Market Size (2018-2033) & (US$ Million)
Figure 34. Germany Peptide and Oligonucleotide CDMO Market Size (2018-2033) & (US$ Million)
Figure 35. France Peptide and Oligonucleotide CDMO Market Size (2018-2033) & (US$ Million)
Figure 36. U.K. Peptide and Oligonucleotide CDMO Market Size (2018-2033) & (US$ Million)
Figure 37. Italy Peptide and Oligonucleotide CDMO Market Size (2018-2033) & (US$ Million)
Figure 38. Russia Peptide and Oligonucleotide CDMO Market Size (2018-2033) & (US$ Million)
Figure 39. Nordic Countries Peptide and Oligonucleotide CDMO Market Size (2018-2033) & (US$ Million)
Figure 40. Asia-Pacific Peptide and Oligonucleotide CDMO Market Share by Region (2018-2033)
Figure 41. China Peptide and Oligonucleotide CDMO Market Size (2018-2033) & (US$ Million)
Figure 42. Japan Peptide and Oligonucleotide CDMO Market Size (2018-2033) & (US$ Million)
Figure 43. South Korea Peptide and Oligonucleotide CDMO Market Size (2018-2033) & (US$ Million)
Figure 44. Southeast Asia Peptide and Oligonucleotide CDMO Market Size (2018-2033) & (US$ Million)
Figure 45. India Peptide and Oligonucleotide CDMO Market Size (2018-2033) & (US$ Million)
Figure 46. Australia Peptide and Oligonucleotide CDMO Market Size (2018-2033) & (US$ Million)
Figure 47. Latin America Peptide and Oligonucleotide CDMO Market Share by Country (2018-2033)
Figure 48. Mexico Peptide and Oligonucleotide CDMO Market Size (2018-2033) & (US$ Million)
Figure 49. Brazil Peptide and Oligonucleotide CDMO Market Size (2018-2033) & (US$ Million)
Figure 50. Middle East & Africa Peptide and Oligonucleotide CDMO Market Share by Country (2018-2033)
Figure 51. Turkey Peptide and Oligonucleotide CDMO Market Size (2018-2033) & (US$ Million)
Figure 52. Saudi Arabia Peptide and Oligonucleotide CDMO Market Size (2018-2033) & (US$ Million)
Figure 53. UAE Peptide and Oligonucleotide CDMO Market Size (2018-2033) & (US$ Million)
Figure 54. Bottom-up and Top-down Approaches for This Report

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries